Karyopharm Therapeutics Inc. Debt Securities, Available-for-sale, Unrealized Gain
Karyopharm Therapeutics Inc. (KPTI) reported Debt Securities, Available-for-sale, Unrealized Gain of $68.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-02-13
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2024-12-31 was -$111.00K, a 216.84% decline year-over-year.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2024-09-30 was $168.00K.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2024-06-30 was -$19.00K.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2024-03-31 was $30.00K, a 50.00% increase year-over-year.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for fiscal 2024 was $68.00K, a 29.17% decline from fiscal 2023.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for fiscal 2023 was $96.00K, a 2300.00% increase from fiscal 2022.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for fiscal 2022 was $4.00K, a 0.00% change from fiscal 2021.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized gain for fiscal 2021 was $4.00K, a 98.78% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $57.00K derived: sum of 2 quarters · filed 2026-02-13 | $38.00K derived: sum of 3 quarters · filed 2026-02-13 | $68.00K 10-K · filed 2026-02-13 |
| 2024-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $149.00K derived: sum of 2 quarters · filed 2024-11-05 | $179.00K 10-Q · filed 2024-11-05 | $274.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2024-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $11.00K 10-Q · filed 2024-08-06 | $106.00K derived: sum of 3 quarters · filed 2025-02-19 | $106.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2024-03-31 | $30.00K 10-Q · filed 2024-05-08 | $125.00K derived: sum of 2 quarters · filed 2025-02-19 | $125.00K derived: sum of 3 quarters · filed 2025-02-19 | $106.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $95.00K derived: sum of 2 quarters · filed 2025-02-19 | $76.00K derived: sum of 3 quarters · filed 2025-02-19 | $96.00K 10-K · filed 2025-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$19.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.00K 10-Q · filed 2023-11-02 | $4.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.00K 10-Q · filed 2023-08-02 | $4.00K derived: sum of 3 quarters · filed 2024-02-29 | $5.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $20.00K 10-Q · filed 2023-05-04 | $23.00K derived: sum of 2 quarters · filed 2024-02-29 | $24.00K derived: sum of 3 quarters · filed 2024-02-29 | $19.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.00K derived: sum of 2 quarters · filed 2024-02-29 | -$1.00K derived: sum of 3 quarters · filed 2024-02-29 | $4.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$4.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.00K 10-Q · filed 2022-11-03 | |
| 2022-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $5.00K 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $4.00K 10-K · filed 2023-02-17 | |||
| 2020-12-31 | $327.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |